Lars Fokdal1, Kari Tanderup2, Richard Pötter3, Alina Sturdza3, Kathrin Kirchheiner3, Cyrus Chargari4, Ina Maria Jürgenliemk-Schulz5, Barbara Segedin6, Li-Tee Tan7, Peter Hoskin8, Umesh Mahantshetty9, Kjersti Bruheim10, Bhavana Rai11, Christian Kirisits3, Jacob Christian Lindegaard2. 1. Department of Oncology, Aarhus University Hospital, Denmark. Electronic address: Larfok@rm.dk. 2. Department of Oncology, Aarhus University Hospital, Denmark. 3. Department of Radiation Oncology, Medical University of Vienna, Austria. 4. Department of Radiotherapy, Gustave-Roussy, France. 5. Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. 6. Department of Radiation Oncology, Institute of Oncology Ljubljana, Slovenia. 7. Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals, United Kingdom; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals, United Kingdom. 8. Mount Vernon Cancer Centre, Northwood, United Kingdom. 9. Department of Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India. 10. Department of Oncology, Oslo University Hospital, Oslo, Norway. 11. Department of Radiation Oncology, Regional Cancer Centre, Chandigarh, India.
Abstract
PURPOSE: Ureteral stricture is a rare but severe side effect of radiation therapy for locally advanced cervical cancer. This report describes the incidence and risk factors for ureteral stricture in a large patient cohort treated with 3-dimensional image guided adaptive brachytherapy and radiochemotherapy within the EMBRACE studies. METHODS AND MATERIALS: A total of 1860 patients were included. Treatment consisted of external beam radiation therapy (45-50 Gy in 25-30 fractions), concomitant cisplatin, and image guided adaptive brachytherapy. Grade 3 to 4 ureteral strictures were assessed with Common Terminology Criteria for Adverse Events v. 3.0. Risk factors for grade 3 to 4 ureteral stricture were analyzed. These factors included age, hydronephrosis on imaging at time of diagnosis, TNM stage, high-risk clinical target volume, laparoscopic staging, chemotherapy, radiation therapy doses to targets and organs at risk, applicator type, intracavitary versus intracavitary/interstitial technique, and dose rate. RESULTS: At a median follow-up of 34 months (range, 2-163), 31 patients received diagnoses of grade 3 to 4 ureteral stricture. Actuarial 3- and 5-year risk for ureteral stricture grade 3 to 4 was 1.7% and 2.1%, respectively, for all patients. Advanced tumor stage T3-4 with hydronephrosis at diagnosis was the only independent risk factors for ureteral stricture (P = .01). Patients with TNM stage T1 (n = 359) had a low risk of 0.4% and 1.0% at 3 and 5 years, and those with T2 (n = 1085) had a low risk of 1.0% and 1.0% at 3 and 5 years, respectively. Patients (n = 274) with T3-T4 without hydronephrosis at diagnosis had a 3- and 5-year risk of 2.2% and 4.8%, respectively, compared with 11.5% and 11.5%, respectively, in those with baseline hydronephrosis (n = 142). CONCLUSIONS: Severe to life-threatening ureteral stricture occurs rarely in patients with locally advanced cervical cancer with T1-2 tumors. The risk for ureteral stricture is significantly increased in patients with T3-T4 tumors with hydronephrosis at diagnosis.
PURPOSE: Ureteral stricture is a rare but severe side effect of radiation therapy for locally advanced cervical cancer. This report describes the incidence and risk factors for ureteral stricture in a large patient cohort treated with 3-dimensional image guided adaptive brachytherapy and radiochemotherapy within the EMBRACE studies. METHODS AND MATERIALS: A total of 1860 patients were included. Treatment consisted of external beam radiation therapy (45-50 Gy in 25-30 fractions), concomitant cisplatin, and image guided adaptive brachytherapy. Grade 3 to 4 ureteral strictures were assessed with Common Terminology Criteria for Adverse Events v. 3.0. Risk factors for grade 3 to 4 ureteral stricture were analyzed. These factors included age, hydronephrosis on imaging at time of diagnosis, TNM stage, high-risk clinical target volume, laparoscopic staging, chemotherapy, radiation therapy doses to targets and organs at risk, applicator type, intracavitary versus intracavitary/interstitial technique, and dose rate. RESULTS: At a median follow-up of 34 months (range, 2-163), 31 patients received diagnoses of grade 3 to 4 ureteral stricture. Actuarial 3- and 5-year risk for ureteral stricture grade 3 to 4 was 1.7% and 2.1%, respectively, for all patients. Advanced tumor stage T3-4 with hydronephrosis at diagnosis was the only independent risk factors for ureteral stricture (P = .01). Patients with TNM stage T1 (n = 359) had a low risk of 0.4% and 1.0% at 3 and 5 years, and those with T2 (n = 1085) had a low risk of 1.0% and 1.0% at 3 and 5 years, respectively. Patients (n = 274) with T3-T4 without hydronephrosis at diagnosis had a 3- and 5-year risk of 2.2% and 4.8%, respectively, compared with 11.5% and 11.5%, respectively, in those with baseline hydronephrosis (n = 142). CONCLUSIONS: Severe to life-threatening ureteral stricture occurs rarely in patients with locally advanced cervical cancer with T1-2 tumors. The risk for ureteral stricture is significantly increased in patients with T3-T4 tumors with hydronephrosis at diagnosis.
Authors: Hima Bindu Musunuru; Phillip M Pifer; Pranshu Mohindra; Kevin Albuquerque; Sushil Beriwal Journal: Indian J Med Res Date: 2021-08 Impact factor: 5.274
Authors: Lukas John Hefermehl; Stefan Tritschler; Alexander Kretschmer; Vincent Beck; Christian G Stief; Boris Schlenker; Frank Strittmatter Journal: Investig Clin Urol Date: 2020-03-09
Authors: Clinton T Yeaman; Andrew Winkelman; Kimberly Maciolek; Mei Tuong; Perri Nelson; Chandler Morris; Stephen Culp; Sumit Isharwal; Tracey L Krupski Journal: BMC Urol Date: 2021-08-04 Impact factor: 2.264